Scarica l'app Stockscreener
0.6949
2.88%
-0.0206
Dopo l'orario di chiusura:
.70
0.0051
+0.73%
Precedente Chiudi:
$0.7155
Aprire:
$0.7299
Volume 24 ore:
166.13K
Relative Volume:
0.31
Capitalizzazione di mercato:
$31.77M
Reddito:
-
Utile/perdita netta:
$-81.22M
Rapporto P/E:
-0.2348
EPS:
-2.96
Flusso di cassa netto:
$-74.41M
1 W Prestazione:
-16.25%
1M Prestazione:
-28.36%
6M Prestazione:
-27.61%
1 anno Prestazione:
+4.50%
Intervallo 1D:
$0.684
$0.7299
Intervallo di 1 settimana:
$0.67
$0.8547
Portata 52W:
$0.5001
$1.93
Xilio Therapeutics Inc Stock (XLO) Company Profile
Nome
Xilio Therapeutics Inc
Settore
Industria
Telefono
617-833-1027
Indirizzo
828 WINTER STREET, WALTHAM
Confronta XLO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.6949 | 31.77M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-21 | Iniziato | Chardan Capital Markets | Buy |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-16 | Iniziato | Cowen | Outperform |
| 2021-11-16 | Iniziato | Guggenheim | Buy |
| 2021-11-16 | Iniziato | Morgan Stanley | Overweight |
| 2021-11-16 | Iniziato | Raymond James | Outperform |
Mostra tutto
Xilio Therapeutics Inc Borsa (XLO) Ultime notizie
Xilio shares tumble after mixed vilastobart data - The Pharma Letter
Vilastobart set apart? Xilio phase II combo performs in CRC - BioWorld Online
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Marketscreener.com
Xilio Therapeutics Advances with Phase 2 Trial Data - TipRanks
Xilio Therapeutics Announces Initial Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian
Xilio Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - Marketscreener.com
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Awards 60,000-Share Stock Option Grant to New Employee at $0.955 - StockTitan
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Rises By 221.7% - Defense World
Geode Capital Management LLC Grows Position in Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World
Xilio Therapeutics Inc [XLO] stock for 6,841 USD was sold by Frankenfield Christopher James - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 31.9% in December - Defense World
Xilio Therapeutics Enters into Additional Private Placement with Gilead; Issues Securities at $25 Million Aggregate Investment - Defense World
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock - Investing.com India
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com - Investing.com Australia
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - GlobeNewswire
Xilio Therapeutics Hires Caroline Hensley as Chief Legal Officer - Bloomberg Law
Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - The Bakersfield Californian
Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan
Xilio Therapeutics, Inc. Appoints Caroline Hensley as chief legal officer - Marketscreener.com
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Increases By 317.4% - Defense World
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - MSN
Here's Why We're Not Too Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Yahoo Finance
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 89.4% in November - Defense World
Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00 - Defense World
Xilio to present new cancer treatment data at SITC By Investing.com - Investing.com Australia
Xilio Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Xilio Therapeutics Inc. (XLO) Quarterly 10-Q Report - Quartzy
Xilio to present new cancer treatment data at SITC - Investing.com
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - citybiz
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors - GlobeNewswire
Xilio's Cancer Drug Shows Promise: Liver Metastasis Resolution in Clinical Trial | XLO Stock News - StockTitan
Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.
Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St
Xilio Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of - The Bakersfield Californian
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan
Xilio Therapeutics Inc Azioni (XLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):